Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients

Su, Tung‐Hung; Kao, Jia‐Horng

doi:10.1111/liv.13253

Cited by 190 publications

(180 citation statements)

References 31 publications

(92 reference statements)

Supporting

Mentioning

164

Contrasting

Unclassified

Order By: Relevance

“…43 The most likely explanation for these findings is the presence of concomitant liver injury such as alcoholic or non-alcoholic fatty liver disease. 34,44 In contrast, transient ALT flares may indicate some level of immune reconstitution and can be associated with favourable outcomes. 1,45,46 The loss of HBsAg is regarded as the optimal treatment endpoint, termed 'functional cure', but it is only rarely achieved with our current antiviral armamentarium.…”

Section: Recommendationsmentioning

confidence: 99%

“…It therefore represents the cornerstone endpoint of all our current therapeutic attempts. 1,25,[34][35][36][37][38][39][40] The level of HBV DNA suppression that should be attained in order to achieve these benefits is not well defined, but inferred that the lower, the better. Treatment-induced HBeAg loss and seroconversion to antiHBe characterises the induction of a partial immune control often leading to a low replicative phase of the chronic HBV infection.…”

Section: Recommendationsmentioning

confidence: 99%

“…In HBeAg-positive CHB, 5 years of ETV achieve a 99% cumulative probability of virologic response and 53% probability of HBeAg loss. 26 After 5 years of TDF treatment in patients with HBeAg-positive CHB, 97% of those on-treatment had virologic response and 73% had normal ALT, 34 while HBeAg loss was present in 49%, HBeAg seroconversion in 40%, HBsAg loss in 10% and HBsAg seroconversion in 8%.…”

Section: Efficacy Recommendationsmentioning

confidence: 99%

“…1,34 Moreover, complications of pre-existing decompensated cirrhosis, particularly at an early stage of decompensation, improve or even disappear and the need for liver transplantation is dramatically reduced.…”

Section: Long-term Outcome During Na Recommendationsmentioning

confidence: 99%

See 3 more Smart Citations

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Lampertico¹,

Agarwal²,

Berg³

et al. 2017

Journal of Hepatology

4,000

3,081

View full text Add to dashboard Cite

Section: Recommendationsmentioning

confidence: 99%

Section: Recommendationsmentioning

confidence: 99%

Section: Efficacy Recommendationsmentioning

confidence: 99%

Section: Long-term Outcome During Na Recommendationsmentioning

confidence: 99%

See 2 more Smart Citations

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Lampertico¹,

Agarwal²,

Berg³

et al. 2017

Journal of Hepatology

4,000

3,081

View full text Add to dashboard Cite

“…Several large population-based and international studies have reveal that antiviral therapy could reduce the incidence of hepatic failure, cirrhosis, HCC, and mortality in CHB patients without alcoholism [33][34][35][36][37][38][39][40].…”

Section: Treatment In Patients With Concomitant Hbv Infection and Alcmentioning

confidence: 99%

Treatment and Prognosis of Hepatitis B Virus Concomitant with Alcoholism

Lin¹,

Lin²,

Yang³

2017

Advances in Treatment of Hepatitis C and B

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection is a global disease worldwide. The Asia-Pacific regionhas a high prevalence of viral hepatitis, and Taiwan is a region of high prevalence of chronic hepatitis B (CHB) with increasing alcoholic liver disease. We have investigated the prognosis and treatment of patients with concomitant hepatitis B virus (HBV) infection and alcoholism. The 10-year cumulative incidence of hepatocellular carcinoma (HCC) is much higher in patients with concomitant alcoholism and HBV infection than in those with alcoholism or HBV infection alone. Treatment with antiviral therapy and abstinence may be started in patients with decompensated cirrhosis and compensated cirrhosis with high HBV DNA. In pre-cirrhotic cases, treatment with antiviral therapy and abstinence may be started in patients with persistently elevated ALT levels and high HBV DNA, and significant fibrosis with minimal elevated or normal ALT levels and mild high HBV DNA. Treatment with antiviral therapy and abstinence reduces the incidence of HCC in patients with concomitant HBV infection and alcoholism. In conclusion, patients with concomitant HBV infection and alcoholism have high incidence of cirrhosis, HCC, and mortality. Treatment with antiviral therapy and abstinence may be started to reduce the incidence of cirrhosis, HCC, and mortality in these patients.

show abstract

Association of Heavy Alcohol Intake and ALDH2 rs671 Polymorphism With Hepatocellular Carcinoma and Mortality in Patients With Hepatitis B Virus–Related Cirrhosis

et al. 2022

View full text Add to dashboard Cite

IMPORTANCEThe role of heavy alcohol intake, aldehyde dehydrogenase 2 gene (ALDH2) rs671 polymorphism, and hepatitis B virus (HBV) infection in hepatocellular carcinoma (HCC) development and mortality remains uncertain. OBJECTIVE To investigate the association of heavy alcohol intake, ALDH2 rs671 polymorphism, and HBV infection with HCC development and mortality in patients with cirrhosis. DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study enrolled patients with cirrhosis with heavy alcoholism or/and HBV infection from January 2005 to December 2020. Patients were followed up through June 30, 2021. The current data analysis was performed from August 2021 to April 2022. Patients from 3 tertiary hospitals in Taiwan were enrolled.EXPOSURES Heavy alcohol intake was defined as consuming more than 80 g of ethanol each day for at least 5 years. MAIN OUTCOMES AND MEASURESThe primary end point was newly developed HCC. The secondary end point was overall mortality. RESULTSOf 1515 patients with cirrhosis (342 with concomitant heavy alcoholism and HBV infection, 796 with HBV infection alone, and 377 with heavy alcoholism alone), 1277 (84.3%) were men, and their mean (SD) age was 49.5 (10.2) years; 746 patients had blood samples collected for ALDH2 rs671 polymorphism analysis. The 10-year cumulative incidences of HCC and mortality were significantly higher in patients with cirrhosis with concomitant HBV infection and alcoholism than in those with HBV infection alone or alcoholism alone. Heavy alcohol intake and the ALDH2 rs671 genotype (GA/AA) were associated with significantly increased risk of HCC and mortality in patients with HBV-related cirrhosis. In patients with cirrhosis with concomitant HBV infection and alcoholism, factors associated with risk of HCC were baseline serum HBV DNA (adjusted hazard ratio [aHR], 3.24;

show abstract

Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients

Abstract: Four-year entecavir therapy significantly reduces the risk of HCC, cirrhotic events and mortality in patients with CHB-related cirrhosis.

Cited by 190 publications

References 31 publications

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Treatment and Prognosis of Hepatitis B Virus Concomitant with Alcoholism

Association of Heavy Alcohol Intake and ALDH2 rs671 Polymorphism With Hepatocellular Carcinoma and Mortality in Patients With Hepatitis B Virus–Related Cirrhosis

Contact Info

Product

Resources

About